Mapping of the UGT1A locus identifies an uncommon coding variant that affects mRNA expression and protects from bladder cancer.

A recent genome-wide association study of bladder cancer identified the UGT1A gene cluster on chromosome 2q37.1 as a novel susceptibility locus. The UGT1A cluster encodes a family of UDP-glucuronosyltransferases (UGTs), which facilitate cellular detoxification and removal of aromatic amines. Bioactivated forms of aromatic amines found in tobacco smoke and industrial chemicals are the main risk factors for bladder cancer. The association within the UGT1A locus was detected by a single nucleotide polymorphism (SNP) rs11892031. Now, we performed detailed resequencing, imputation and genotyping in this region. We clarified the original genetic association detected by rs11892031 and identified an uncommon SNP rs17863783 that explained and strengthened the association in this region (allele frequency 0.014 in 4035 cases and 0.025 in 5284 controls, OR = 0.55, 95%CI = 0.44-0.69, P = 3.3 × 10(-7)). Rs17863783 is a synonymous coding variant Val209Val within the functional UGT1A6.1 splicing form, strongly expressed in the liver, kidney and bladder. We found the protective T allele of rs17863783 to be associated with increased mRNA expression of UGT1A6.1 in in-vitro exontrap assays and in human liver tissue samples. We suggest that rs17863783 may protect from bladder cancer by increasing the removal of carcinogens from bladder epithelium by the UGT1A6.1 protein. Our study shows an example of genetic and functional role of an uncommon protective genetic variant in a complex human disease, such as bladder cancer.

[1]  Stephen J. Chanock,et al.  Current status of genome-wide association studies in cancer , 2011, Human Genetics.

[2]  N. Malats,et al.  Urinary pH, cigarette smoking and bladder cancer risk. , 2011, Carcinogenesis.

[3]  Qianqian Zhu,et al.  A genome-wide comparison of the functional properties of rare and common genetic variants in humans. , 2011, American journal of human genetics.

[4]  David B. Goldstein,et al.  The Importance of Synthetic Associations Will Only Be Resolved Empirically , 2011, PLoS biology.

[5]  J. Ioannidis,et al.  Genome-wide significant associations for variants with minor allele frequency of 5% or less--an overview: A HuGE review. , 2010, American journal of epidemiology.

[6]  D. Altshuler,et al.  A map of human genome variation from population-scale sequencing , 2010, Nature.

[7]  William Wheeler,et al.  A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci , 2010, Nature Genetics.

[8]  Sharon R Grossman,et al.  Integrating common and rare genetic variation in diverse human populations , 2010, Nature.

[9]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[10]  Olle Melander,et al.  From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus , 2010, Nature.

[11]  Samuel P. Dickson,et al.  Interpretation of association signals and identification of causal variants from genome-wide association studies. , 2010, American journal of human genetics.

[12]  S. Marques,et al.  The clinical application of UGT1A1 pharmacogenetic testing: Gene-environment interactions , 2010, Human Genomics.

[13]  David B. Goldstein,et al.  Rare Variants Create Synthetic Genome-Wide Associations , 2010, PLoS biology.

[14]  A. Rai,et al.  Introduction to urinalysis: historical perspectives and clinical application. , 2010, Methods in molecular biology.

[15]  Judy H. Cho,et al.  Finding the missing heritability of complex diseases , 2009, Nature.

[16]  Ming-Huei Chen,et al.  Genome-wide association meta-analysis for total serum bilirubin levels. , 2009, Human molecular genetics.

[17]  G. Abecasis,et al.  Common variants in the SLCO1B3 locus are associated with bilirubin levels and unconjugated hyperbilirubinemia. , 2009, Human Molecular Genetics.

[18]  F. Collins,et al.  Potential etiologic and functional implications of genome-wide association loci for human diseases and traits , 2009, Proceedings of the National Academy of Sciences.

[19]  K. Frazer,et al.  Common vs. rare allele hypotheses for complex diseases. , 2009, Current opinion in genetics & development.

[20]  P. Donnelly,et al.  A Flexible and Accurate Genotype Imputation Method for the Next Generation of Genome-Wide Association Studies , 2009, PLoS genetics.

[21]  R. Fujiwara,et al.  Expression of UGT1A and UGT2B mRNA in Human Normal Tissues and Various Cell Lines , 2008, Drug Metabolism and Disposition.

[22]  A. Morris,et al.  Evaluating the effects of imputation on the power, coverage, and cost efficiency of genome-wide SNP platforms. , 2008, American journal of human genetics.

[23]  W. Bodmer,et al.  Common and rare variants in multifactorial susceptibility to common diseases , 2008, Nature Genetics.

[24]  John D Potter,et al.  Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. , 2008, JAMA.

[25]  C. Polychronakos.  Common and rare alleles as causes of complex phenotypes , 2008, Current atherosclerosis reports.

[26]  M. Spitz,et al.  Shifting paradigm of association studies: value of rare single-nucleotide polymorphisms. , 2008, American journal of human genetics.

[27]  L. Kiemeney.  Hereditary bladder cancer , 2008, Scandinavian journal of urology and nephrology. Supplementum.

[28]  N. Malats,et al.  Risk of Bladder Cancer Associated with Family History of Cancer: Do Low-Penetrance Polymorphisms Account for the Increase in Risk? , 2007, Cancer Epidemiology Biomarkers & Prevention.

[29]  J. Higgins,et al.  Joint effects of the N-acetyltransferase 1 and 2 (NAT1 and NAT2) genes and smoking on bladder carcinogenesis: a literature-based systematic HuGE review and evidence synthesis. , 2007, American journal of epidemiology.

[30]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[31]  Teruhiko Yoshida,et al.  Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28 , 2007, Pharmacogenetics and genomics.

[32]  H. Campbell,et al.  Commentary: rare alleles, modest genetic effects and the need for collaboration. , 2007, International journal of epidemiology.

[33]  Jae K. Lee,et al.  Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study , 2007, Molecular Cancer Therapeutics.

[34]  D. Michaud,et al.  Polymorphisms in GSTT1, GSTM1, NAT1 and NAT2 genes and bladder cancer risk in men and women , 2006, BMC Cancer.

[35]  Y. Lotan,et al.  Economic impact of screening for bladder cancer using bladder tumor markers: a decision analysis. , 2006, Urologic oncology.

[36]  Lon R Cardon,et al.  Evaluating coverage of genome-wide association studies , 2006, Nature Genetics.

[37]  R. Remmel,et al.  Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer , 2006, Oncogene.

[38]  A. Zlotta.  NAT2 Slow Acetylation, GSTM1 Null Genotype, and Risk of Bladder Cancer: Results from the Spanish Bladder Cancer Study and Meta-Analyses , 2006 .

[39]  S. Nagar,et al.  Pharmacogenetics of Uridine Diphosphoglucuronosyltransferase (UGT) 1A Family Members and its Role in Patient Response to Irinotecan , 2006, Drug metabolism reviews.

[40]  N. Saijo,et al.  Haplotype structures of the UGT1A gene complex in a Japanese population , 2006, The Pharmacogenomics Journal.

[41]  Erik K. Malm,et al.  A Human Protein Atlas for Normal and Cancer Tissues Based on Antibody Proteomics* , 2005, Molecular & Cellular Proteomics.

[42]  D. Clayton,et al.  Genome-wide association studies: theoretical and practical concerns , 2005, Nature Reviews Genetics.

[43]  Mark Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[44]  H. Kikuchi.  [Urinary pH]. , 2004, Nihon rinsho. Japanese journal of clinical medicine.

[45]  S. Hecht.  Tobacco carcinogens, their biomarkers and tobacco-induced cancer , 2004, Nature Reviews Cancer.

[46]  Jinhua Wang,et al.  ESEfinder: a web resource to identify exonic splicing enhancers , 2003, Nucleic Acids Res..

[47]  Alberto Redaelli,et al.  The health economics of bladder cancer: a comprehensive review of the published literature. , 2003, PharmacoEconomics.

[48]  A. Di Rienzo,et al.  Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. , 2002, Pharmacogenetics.

[49]  D. Hein.  Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. , 2002, Mutation research.

[50]  R. Tukey,et al.  Pharmacogenomics of human UDP-glucuronosyltransferases and irinotecan toxicity. , 2002, Molecular pharmacology.

[51]  E. Lander,et al.  On the allelic spectrum of human disease. , 2001, Trends in genetics : TIG.

[52]  J. Pritchard.  Are rare variants responsible for susceptibility to complex diseases? , 2001, American journal of human genetics.

[53]  Matthew W. Pennington,et al.  Thirteen UDPglucuronosyltransferase genes are encoded at the human UGT1 gene complex locus. , 2001, Pharmacogenetics.

[54]  H. Dietrich,et al.  Ludwig Rehn (1849–1930) – Pioneering findings on the aetiology of bladder tumours , 2001, World Journal of Urology.

[55]  R. Tukey,et al.  Human UDP-glucuronosyltransferases: metabolism, expression, and disease. , 2000, Annual review of pharmacology and toxicology.

[56]  A. Chakravarti.  Population genetics—making sense out of sequence , 1999, Nature Genetics.

[57]  E. Lander.  The New Genomics: Global Views of Biology , 1996, Science.

[58]  T. Remer,et al.  Potential renal acid load of foods and its influence on urine pH. , 1995, Journal of the American Dietetic Association.

[59]  T. Shirai.  Etiology of bladder cancer. , 1993, Seminars in urology.

[60]  K. Bock.  Roles of UDP-glucuronosyltransferases in chemical carcinogenesis. , 1991, Critical reviews in biochemistry and molecular biology.

[61]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[62]  M. Knowles,et al.  Metabolism and binding of benzo(a)pyrene and 2-acetylaminofluorene by short-term organ cultures of human and rat bladder. , 1982, Cancer research.

[63]  B. Ketterer,et al.  Formation of 3-(glutathion-S-YL)-N-methyl-4-aminoazobenzene and inhibition of aminoazo dye-nucleic acid binding in vitro by reaction of glutathione with metabolically-generated N-methyl-4-aminoazobenzene-N-sulfate. , 1980, Chemico-biological interactions.

[64]  J. Radomski,et al.  N-Glucuronidation of N-hydroxy aromatic amines: a mechanism for their transport and bladder-specific carcinogenicity. , 1979, Toxicology and applied pharmacology.

[65]  R. Case,et al.  Tumours Of The Urinary Bladder in Workmen Engaged in the Manufacture and Use Of Certain Dyestuff Intermediates In The British Chemical Industry. Part I. The Role Of Aniline, Benzidine, Alpha-Naphthylamine, And Beta-Naphthylamine , 1954, British journal of industrial medicine.